NOVAVAX INC
No SEC Form 4 filings for $NVAX in the last 30 days.
See all $NVAX insider activity →Several healthcare stocks fell after bipartisan lawmakers introduced the Protecting Approved Care Act, which aims to reform Medicare Advantage plans. The bill could increase medical loss ratios and administrative burdens for insurers. Astrana Health (ASTH) fell 2.7%, Clover Health (CLOV) 4.8%, Alignment Healthcare (ALHC) 12.6%, and Novavax (NVAX) 3.6%.
Novavax Inc. shares rose 1.80% to $9.59 on Monday, despite broader market declines, marking two days of gains. The NASDAQ and Dow Jones indices fell 0.56% and 0.29%, respectively.
Novavax (NVAX) announced at the Cantor Fitzgerald Global Healthcare Conference its shift to a technology licensing model, focusing on its Matrix-M adjuvant and nanoparticle protein system. The company reported $800M in payments from Pfizer and Sanofi, with $200M in near-term milestones. Novavax aims for non-GAAP profitability by 2028, requiring over $150M in revenue. It has partnerships with top pharmaceutical companies and is exploring applications in infectious diseases and oncology.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning NVAX (NOVAVAX INC). Coverage has skewed bearish: 0 bullish, 1 neutral, and 1 bearish.
Recent NVAX coverage spans regulation, market movers and technology.
Regulatory environment adds uncertainty to reimbursement outlook for biotech products.
Small intraday rally with no disclosed catalyst.
The licensing revenue stream and cost cuts could improve cash runway and support a path to profitability by 2028.
Despite low revenue, beating estimates sparked a strong rally.
Novavax gains a new FDA‑cleared COVID product, improving its pipeline credibility.
AlphAI scores every news story that mentions NVAX with an AI model for sentiment and relevance, and aggregates insider trades from NOVAVAX INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Several healthcare stocks fell after bipartisan lawmakers introduced the Protecting Approved Care Act, which aims to reform Medicare Advantage plans. The bill could increase medical loss ratios and administrative burdens for insurers. Astrana Health (ASTH) fell 2.7%, Clover Health (CLOV) 4.8%, Alignment Healthcare (ALHC) 12.6%, and Novavax (NVAX) 3.6%.
2 min readNovavax Inc. shares rose 1.80% to $9.59 on Monday, despite broader market declines, marking two days of gains. The NASDAQ and Dow Jones indices fell 0.56% and 0.29%, respectively.
1 min readNovavax (NVAX) announced at the Cantor Fitzgerald Global Healthcare Conference its shift to a technology licensing model, focusing on its Matrix-M adjuvant and nanoparticle protein system. The company reported $800M in payments from Pfizer and Sanofi, with $200M in near-term milestones. Novavax aims for non-GAAP profitability by 2028, requiring over $150M in revenue. It has partnerships with top pharmaceutical companies and is exploring applications in infectious diseases and oncology.
2 min readUnited Therapeutics (UTHR) stock rose 4.3% post-earnings, trading at $214.36. Myriad Genetics (MYGN) reported $190.7M revenue, down 10.5% YoY, missing estimates, and guidance fell short, causing a 40.9% stock drop to $3.18. Gilead Sciences (GILD) reported $7.8B revenue, up 10.2% YoY, beating estimates, with stock up 8.1% to $146.16. Novavax (NVAX) reported $56.7M revenue, down 76.3% YoY, but beat estimates, with stock up 32.2% to $10.18.
3 min readThe FDA approved updated COVID-19 vaccines for the 2026-2027 season from Moderna, Pfizer, and Novavax-Sanofi, targeting the XFG subvariant. Pfizer's Comirnaty XFG, Moderna's SpikeVax and mNEXSPIKE, and Novavax-Sanofi's Nuvaxovid are approved for specific age groups and high-risk individuals. CDC recommendations from 2025-2026 remain in effect. Vaccines are available at pharmacies and healthcare centers, with coverage by insurers, Medicaid, and Medicare.
2 min readIonis (IONS) and Milestone (MIST) gained FDA approvals for neurology and cardiology drugs. Biogen (BIIB) and AstraZeneca (AZN) also received regulatory nods for Alzheimer's and cancer treatments. Novavax (NVAX) secured global approvals for its COVID-19 vaccine. TScan (TCRX) and Novartis (NVS) announced job cuts. Novartis (NVS) and HUTCHMED (HCM) struck deals worth up to $3.2B and $1.295B respectively.
3 min readThe FDA approved new COVID-19 vaccines from Moderna, Pfizer-BioNTech, and Novavax-Sanofi for 2026-27, targeting current variants. Moderna received approval for two vaccines. Distribution will be limited to specific age groups and high-risk individuals, with availability expected in the fall.
2 min readThe FDA approved updated 2026-2027 COVID-19 vaccines from Pfizer-BioNTech, Moderna, and Novavax targeting the JN.1-lineage XFG variant. Approvals cover high-risk populations, including adults 65+ and those with underlying conditions. Pfizer and Moderna's mRNA vaccines and Novavax's protein-based vaccine are now authorized for distribution.
2 min readThe FDA approved updated COVID-19 vaccines from Moderna, Pfizer-BioNTech, and Novavax (via Sanofi and Takeda) for the 2026–2027 season, targeting the XFG variant. The approvals are based on clinical and real-world data, with Pfizer and BioNTech's vaccine set to ship immediately. Over five billion doses of their vaccine have been distributed globally.
2 min readThe FDA approved updated COVID-19 vaccines from Pfizer-BioNTech, Moderna, and Novavax-Sanofi targeting the XFG variant, now dominant in 79% of US cases. The vaccines are prioritized for adults 65+ and those with underlying conditions. Pfizer's COMIRNATY XFG, Moderna's mNEXSPIKE and Spikevax, and Novavax-Sanofi's protein-based vaccine are now shipping. CDC recommendation pending for insurance coverage.
2 min read
